Bone Historical Balance Sheet
BBLGW Stock | USD 28.49 0.00 0.00% |
Trend analysis of Bone Biologics Corp balance sheet accounts such as Total Assets of 2.3 M, Cash of 2 M or Cash And Short Term Investments of 2.1 M provides information on Bone Biologics' total assets, liabilities, and equity, which is the actual value of Bone Biologics Corp to its prevalent stockholders. By breaking down trends over time using Bone Biologics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Bone Biologics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bone Biologics Corp is a good buy for the upcoming year.
Bone Biologics Inventory |
|
Bone |
About Bone Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Bone Biologics Corp at a specified time, usually calculated after every quarter, six months, or one year. Bone Biologics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bone Biologics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bone currently owns. An asset can also be divided into two categories, current and non-current.
Bone Biologics Balance Sheet Chart
Add Fundamental
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Current Liabilities
Total Current Liabilities is an item on Bone Biologics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bone Biologics Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most accounts from Bone Biologics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At this time, Bone Biologics' Other Current Liabilities is fairly stable compared to the past year. Total Stockholder Equity is likely to climb to about 3.1 M in 2024, whereas Total Assets are likely to drop slightly above 2.3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Liabilities | 99.9K | 2.5M | 831.4K | 789.8K | Other Stockholder Equity | 77.0M | 77.9M | 83.8M | 47.8M |
Bone Biologics balance sheet Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 12.2K | 51.1K | 43.1K | 47.6K | 263.1K | 250.0K | |
Total Assets | 30.8K | 0.0 | 6.7M | 8.5M | 3.7M | 2.3M | |
Net Debt | 11.3M | 11.7M | (6.7M) | (7.5M) | (3.0M) | (2.9M) | |
Cash | 24.1K | 0.0 | 6.7M | 7.5M | 3.0M | 2.0M | |
Cash And Short Term Investments | 955.4K | 24.1K | 6.7M | 7.5M | 3.0M | 2.1M | |
Liabilities And Stockholders Equity | 30.8K | 13.7M | 6.7M | 8.5M | 3.7M | 3.5M | |
Total Current Assets | 30.8K | 0.0 | 6.7M | 8.5M | 3.7M | 2.3M | |
Other Current Liab | 535.6K | 1.5M | (99.9K) | 2.5M | 470.7K | 925.8K | |
Total Current Liabilities | 578.4K | 13.7M | 99.9K | 2.5M | 831.4K | 789.8K | |
Total Stockholder Equity | (11.9M) | (13.7M) | 6.6M | 5.9M | 2.9M | 3.1M | |
Retained Earnings | (67.0M) | (68.9M) | (70.5M) | (72.0M) | (80.9M) | (76.9M) | |
Other Stockholder Equity | 55.1M | 55.2M | 77.0M | 77.9M | 83.8M | 47.8M | |
Total Liab | 11.9M | 13.7M | 99.9K | 2.5M | 831.4K | 789.8K | |
Short Long Term Debt Total | 8.2M | 9M | 11.3M | 11.7M | 13.5M | 8.3M | |
Other Current Assets | 105.2K | 85.3K | 6.7K | 956.9K | 711.2K | 746.8K | |
Accounts Payable | 42.9K | 465.4K | 99.9K | 888.46 | 360.7K | 202.9K | |
Non Current Liabilities Total | 11.3M | 12.2M | 99.9K | 888.46 | 799.61 | 759.63 | |
Net Invested Capital | (547.6K) | (2.0M) | 6.6M | 5.9M | 2.9M | 2.1M | |
Net Working Capital | (547.6K) | (13.7M) | 6.6M | 5.9M | 2.9M | 3.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.